Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Detection agent for detecting prostate cancer and application thereof

A prostate cancer, detection agent technology, applied in the direction of microbial determination/inspection, fluorescence/phosphorescence, biochemical equipment and methods, etc., can solve the problems of inability to effectively distinguish prostate hyperplasia, low diagnostic value, missed diagnosis, etc., and achieve naked eye detection. Significant effect, good for observation, large coverage effect

Inactive Publication Date: 2011-08-24
BEIJING GP MEDICAL TECH
View PDF0 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

As a serological marker of PCa, PSA cannot effectively distinguish early PCa from benign prostatic hyperplasia, especially when the PSA is 2-10 ng / ml, it is necessary to study new early PCa diagnostic methods, and effectively screen out PSA in the range of 2-10 ng / ml PCa in
[0005] The diagnostic value of DRE is slightly lower, and only 33% of prostate cancers detected by DRE are confirmed as early localized prostate cancer (Thompson IM, Emst JJ, Gangai MP, et al. Adenocarcinoma of the prostate: results of routine urological screening[J]. J Urol, 1984, 132(4): 690-692.), this diagnostic method will also cause physiological discomfort to the patient
[0006] Transrectal ultrasound-guided biopsy is a common method for preoperative diagnosis of prostate cancer, but it is relatively prone to some complications, such as bleeding (such as hematuria, bloody stool, blood semen), pain, infection, etc., and when the number of detection points is low Occasionally, misdiagnosis occurs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Detection agent for detecting prostate cancer and application thereof
  • Detection agent for detecting prostate cancer and application thereof
  • Detection agent for detecting prostate cancer and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0147] The preparation of embodiment 1GLP TMPRSS2 / ETV1 probe set

[0148] The TMPRSS2 probe was prepared using the random priming method, and the template DNA was labeled as fluorescent red (Tetramthylrhodamine-5-dUTP, purchased from Roche). The probe preparation kit was purchased from Roche (Random Primed DNA Labeling Kit)

[0149] 1. Template DNA preparation (take RP11-814F13 as an example):

[0150] (1) Take an appropriate amount of purchased clone RP11-814F13 (existing in the form of bacterial liquid) for amplification culture;

[0151] (2) Pick a single colony grown on LB solid medium, inoculate it in 20ml LB (containing Amp100μg / ml) liquid medium, culture at 37°C and shake at 250rmp overnight (about 12-14 hours);

[0152] (3) Pour 1.5ml of the culture solution into a 1.5ml eppendorf tube and centrifuge at 12000rmp for 1-2 minutes. Discard the supernatant, and place the centrifuge tube upside down on toilet paper for a few minutes to drain the liquid as much as possible...

Embodiment 2

[0187] The preparation of embodiment 2GLP ERG probe group

[0188] The preparation process of the GLP ERG probe set is the same as the preparation of the GLP TMPRSS2 / ETV1 probe set in Example 1, except that the selected clones are different (the clones specifically used in this example are: RP11-476D17, CTD-2341O18, RP11 -95I21, and RP11-259A4), both include several steps of DNA preparation, probe mixture preparation, probe labeling, mixing, and purification.

Embodiment 3

[0189] The preparation of embodiment 3GLP TMPRSS2 / ETV4 probe group

[0190]The preparation process of the GLP TMPRSS2 / ETV4 probe set is the same as the preparation of the GLPTMPRSS2 / ETV1 probe set in Example 1, except that the selected clones are different (the clones specifically used in this example are: RP11-671L10, AL773578, CTD- 2337B13, CTD-3095D11, CTD-2326M16, CTD-3215I16, and CTC-420I11), all include several steps of DNA preparation, probe mixture preparation, probe labeling, mixing, and purification.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a detection agent for detecting prostate cancer and a reagent kit. Specifically, the detection agent is at least one of the following three probe sets: 1) GLPTMPRSS2 / ETV1 probe set; 2) GLP ERG probe set; and 3) GLPTMPRSS2 / ETV4 probe set. Specifically, the reagent kit comprises the detection agent which is dissolved in a tris-ethylenediaminetetraacetic acid (TE) buffer, wherein the concentration of the probe set is 50 to 300ng / mu l. The invention also relates to application of the detection agent and the reagent kit to the detection of the fusion of a transmembrane protease serine 2 (TMPRSS2) gene and E26 transformation-specific (ETS) family genes, and a method for detecting the fusion of the TMPRSS2 gene and the ETS family genes.

Description

technical field [0001] The invention relates to a detection agent and kit for detecting prostate cancer, the use of the detection agent and kit in detecting the fusion of TMPRSS2 gene and ETS family gene, and a method for detecting the fusion of TMPRSS2 gene and ETS family gene. Background technique [0002] Prostate cancer (hereinafter referred to as "PCa") is a common malignant tumor of the genitourinary system in elderly men. In European and American countries, prostate cancer ranks second among male malignant tumors (Jemal A, Murray T, Samuels A, et a1. Cancer statistics [J]. CA Cancer J, 2003, 53 (1): 5-26.), death second only to lung cancer. In my country, the morbidity and mortality of prostate cancer are increasing year by year, ranking third among urological tumors, and the age of onset is getting younger. [0003] Early PCa is mainly manifested by changes in tissue structure, and the changes in cytopathology are not typical, and the diagnosis is easily affected b...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/68G01N21/64
Inventor 陈忠程晓蕾阴层层吴晓东
Owner BEIJING GP MEDICAL TECH
Features
  • Generate Ideas
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com